Knight Therapeutics Inc.
GUD.TO
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 30.86% | 73.93% | 37.98% | 30.46% | 11.10% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 30.86% | 73.93% | 37.98% | 30.46% | 11.10% |
| Cost of Revenue | 16.22% | 53.86% | 21.50% | 37.79% | 28.20% |
| Gross Profit | 51.28% | 104.56% | 61.05% | 22.77% | -6.34% |
| SG&A Expenses | 27.15% | 35.99% | 40.62% | 20.56% | 9.45% |
| Depreciation & Amortization | 22.18% | 59.84% | 30.69% | 36.83% | -9.09% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.45% | 51.98% | 27.64% | 34.43% | 16.85% |
| Operating Income | 3,591.31% | 297.16% | 310.66% | -80.03% | -105.50% |
| Income Before Tax | 86.88% | 3,768.38% | 43.11% | -412.20% | -2,265.11% |
| Income Tax Expenses | 141.02% | 140.46% | 183.21% | 254.78% | -211.30% |
| Earnings from Continuing Operations | 74.06% | 521.98% | -17.18% | -4,517.98% | -542.81% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 74.06% | 521.98% | -17.18% | -4,517.98% | -542.81% |
| EBIT | 3,591.31% | 297.16% | 310.66% | -80.03% | -105.50% |
| EBITDA | 96.40% | 356.88% | 155.96% | 9.90% | -33.44% |
| EPS Basic | 73.69% | 528.76% | -16.25% | -4,700.00% | -554.29% |
| Normalized Basic EPS | 197.00% | 70,900.00% | 189.87% | -0.97% | -940.63% |
| EPS Diluted | 74.36% | 572.66% | -10.88% | -4,933.33% | -543.84% |
| Normalized Diluted EPS | 197.00% | 70,500.00% | 189.87% | -0.97% | -940.63% |
| Average Basic Shares Outstanding | -1.44% | -1.19% | -1.19% | -1.46% | -1.68% |
| Average Diluted Shares Outstanding | -1.44% | -1.15% | -1.07% | -1.46% | -1.68% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |